Exact Sciences: Don’t Deem It Guilty by Association

Wrong place, wrong time.

That’s perhaps the most succinct explanation for Exact Sciences’ one-year bruises (EXAS) stock.

Shares of the genetic testing company are down 65% in the past year, including a 54% drop since early 2022.

Investors shouldn’t be surprised if Exact Sciences coughs up a small valuation during a biotech correction. After all, there was a significant surplus ingrained in valuations across the biotech sector.

But the market leader is just plain disrespected with its current market cap of $6.3 billion. There is also an explanation for this. Wall Street appears to be grouping in Exact Sciences with the doom and gloom of the wider competitive landscape in genetic testing.


Be the first to comment

Leave a Reply

Your email address will not be published.